Previous 10 | Next 10 |
Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings ( SWVL ) ...
Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said it dosed the first patients in two phase 1/2a trials of its RNA interference candidates ARO-MUC5AC and ARO-RAGE, being explored to treat certain muco-obstructive and inflammatory pulmonary diseases. A phase 1/2a stud...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce production the of mucin 5AC (MUC5...
My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...
Should Investors Be Watching These Top Biotech Stocks In The Stock Market Now? Just as most people think that pandemic woes are behind us, we now have the emergence of the monkeypox. While this virus may not be as contagious as the coronavirus, there is still a real cause for concer...
Arrowhead Pharmaceuticals ( ARWR ), a clinical-stage biotech focused on RNA interference (RNAi) therapeutics surged on above average volume on Wednesday in solidarity with several other drug developers targeting the liver disease, non-alcoholic steatohepatitis (NASH). Despite ...
Arrowhead is a leader in RNAi. ARWR has a vast platform. I will wait for the first approval before investing. For further details see: Arrowhead Pharma: We Can Afford To Wait For More Proof
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now. For further details see: Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telli...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%. Gilead's key HIV drug is beginning to feel increased competition from ViiV Healthcare's drug. T...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...